[Urethral stent (Memotherm) for the treatment of benign prostatic hyperplasia].
We used a urethral stent for management of high-age and high-risk patients with benign prostatic hyperplasia (BPH) who needed surgical therapy. Nine patients were treated by this method. Chief complaints were urinary retention in 6 patients, dysuria with much residual urine in 2 and dysuria in 1. Blood loss and complications of the method were minimal. Postoperatively, 8 of the patients were able to void and on the average, residual urine of the patients was approximately 10 ml. Implantation of the urethral stent is a safe and non-invasive therapy for the patients who are unsuitable for invasive therapy.
Noda
Yasuteru
Y
Department of Urology, Osaka Kosei-nenkin Hospital.
Ujike
Takeshi
T
Oka
Daizo
D
Takada
Shingo
S
Fujimoto
Nobumasa
N
Koide
Takuo
T
D000368:Aged; D000369:Aged, 80 and over; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000150:complications / Q000628:therapy*; D011788:Quality of Life; D015607:Stents; D014521:Urethra; D016055:Urinary Retention / Q000209:etiology / Q000628:therapy; D014555:Urination Disorders / Q000209:etiology / Q000628:therapy*